Aster DM Healthcare Limited has completed the mandatory newspaper publication of its unaudited financial results for the quarter and nine months ended December 31, 2025, in compliance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted newspaper clippings to BSE and NSE on January 31, 2026, alongside its previously announced strong Q3FY26 performance and strategic board decisions.

Regulatory Compliance and Publication

The company fulfilled its regulatory obligations by publishing financial results in newspapers on January 31, 2026, with complete transparency measures for stakeholder access.

The published newspaper clippings include Quick Response Code (QR Code) and weblink access to complete financial results, ensuring comprehensive stakeholder accessibility. Company Secretary and Compliance Officer Hemish Purushottam digitally signed the compliance documentation.

Q3FY26 Financial Performance Highlights

The company demonstrated strong operational performance with consolidated EBITDA reaching ₹212.00 crores compared to ₹190.00 crores in the previous year, reflecting robust business fundamentals underlying the regulatory publication.

Consolidated Performance Summary

Standalone Results Overview

For nine months ended December 31, 2025, standalone revenue from operations reached ₹1,960.60 crores with net profit of ₹240.36 crores, while consolidated revenue increased to ₹3,460.84 crores.

Strategic Board Decisions

The Board of Directors approved significant strategic initiatives during their January 30, 2026 meeting, enhancing the company's operational framework and employee engagement strategies.

ESOP Scheme 2026 Approval

Internal Capital Restructuring

The company also acquired additional 5.02% stake in Prerana Hospital Limited for ₹18.59 crores, increasing shareholding to 98.92%. Merger proceedings with Quality Care India Limited continue with NCLT submission completed and stakeholder meetings scheduled between February 27 to March 13, 2026.

Source:

Aster DM Healthcare Limited announced a strategic move to consolidate its ownership in material subsidiary Malabar Institute of Medical Sciences Limited (MIMS) through the acquisition of additional equity shares. The company's Investment and Finance Committee approved this proposal during its meeting held on January 29, 2026.

Acquisition Structure and Shareholding Consolidation

The proposed acquisition is designed to increase Aster DM Healthcare's shareholding in MIMS from the current 79.75% to 100%. The transaction involves purchasing an aggregate 20.25% of MIMS's equity share capital from existing shareholders through a structured letter of offer.

Transaction Timeline and Process

The acquisition process will commence with the dispatch of a letter of offer to MIMS shareholders, with the company estimating transaction completion within three months from the offer dispatch date. The actual number of shares to be purchased depends on the acceptance and participation of existing shareholders in the offer.

MIMS Financial Performance and Background

Malabar Institute of Medical Sciences Limited, established on February 17, 1995, operates in the healthcare services sector with a focus on hospital operations. The company is registered in Govindapuram P.O., Calicut, Kozhikode, Kerala, and operates exclusively within India.

As of March 31, 2025, MIMS reported a turnover of INR 1,118.05 crores and achieved a profit of INR 134.51 crores, demonstrating consistent growth in its healthcare operations.

Regulatory Compliance and Related Party Considerations

The proposed acquisition will not be classified as a related party transaction, as neither the promoters, promoter group, nor any group companies have interest in the entity being acquired. The transaction does not require specific governmental or regulatory approvals, streamlining the acquisition process.

Strategic Impact

This consolidation move aligns with Aster DM Healthcare's strategy to strengthen its control over key healthcare assets. The acquisition will provide complete ownership of MIMS, enhancing operational control and strategic decision-making capabilities within the healthcare services segment.